Novo Nordisk's Summer of Unraveling: When Good Numbers Aren't Enough

Novo Nordisk stock drops 11% in a month amid oral GLP-1 rivalry from Eli Lilly, regulatory issues, and pipeline setbacks, despite raised guidance.

There's a particular kind of discomfort that settles in when a market leader starts talking about sharing the spoils. Mike Doustdar, Novo Nordisk's chief executive, recently framed the obesity race in terms that sounded reassuring on the surface — insisting it isn't a winner-take-all contest where the runner-up walks away empty-handed. Read it again, though, and the statement carries the faint whiff of a company recalibrating its own ambitions.

The market, for its part, isn't buying the comfort. Novo Nordisk shares closed Friday at EUR 39.40, down 2.6 percent on the day, extending a 30-day slide that now stands at 11 percent. The stock sits 28 percent below its 52-week high from January — a gap that puts the euphoria of recent months into stark perspective.

The Pill Problem

The immediate pressure point is oral GLP-1 competition. On August 10, Eli Lilly's Foundayo (orforglipron) secured approval in the UK — the second GLP-1 weight-loss pill to reach the European market, arriving just two months after Novo's own Wegovy pill launched.

The competitive edge is practical rather than scientific: Foundayo requires no food restrictions, while Novo's oral treatment demands an empty stomach and a 30-minute wait before eating. That distinction may sound minor, but in the world of daily medication adherence, convenience often dictates commercial outcomes. Physicians and patients alike tend to favor the simpler regimen.

The Wegovy pill's own numbers do little to dispel the caution. Second-quarter 2026 sales came in at DKK 3.22 billion, slightly below the DKK 3.27 billion analysts had penciled in — despite more than five million prescriptions since its January debut. Volume is there; the monetization is lagging. It's a pattern that could worsen as competitive pressure intensifies.

Regulatory Headwinds and a Narrowing Pipeline

Adding to the operational questions, the FDA has flagged Novo's manufacturing facility in Indiana. Scholar Rock removed the site from its own FDA application for the drug candidate apitegromab after regulators cited the plant following an April inspection. Reuters additionally reported that the Catalent facility in Indiana — now part of the Novo umbrella — received an "Official Action Indicated" designation, a classification signaling serious deficiencies.

On its own, that's a footnote in the supply chain. In the context of a stock already under scrutiny, it becomes another question mark about operational reliability.

The pipeline narrative has also taken hits. Investors had already been focusing on the underwhelming trajectory of the Wegovy pill and a setback in the CagriSema combination therapy study — concerns that predated the August guidance raise that lifted sales and operating profit expectations for the year. Better numbers, weaker story: that's been the Novo Nordisk dialectic all summer.

Doustdar has acknowledged as much, telling Reuters the company needs faster research and is open to smaller acquisitions — explicitly ruling out large, transformative deals. That's a commitment to fine-tuning rather than a grand reset.

Analysts Split, Uncertainty Rules

The analyst community reflects the ambiguity. Berenberg downgraded the stock from Buy to Hold on August 12. The same day, BMO Capital Markets raised its price target to USD 47 from USD 45 and lifted 2026 earnings estimates following the quarterly results — while simultaneously flagging pricing pressure and pointing to the Capital Markets Day in September for more clarity.

These aren't contradictory views so much as two sides of the same uncertainty. Even firms holding onto the operational thesis aren't willing to stick their necks out before that September event.

Defensive Moves and Technical Signals

Novo hasn't been idle on other fronts. The August 10 announcement of a strategic partnership with Amazon Web Services — aimed at accelerating drug discovery through agentic AI and cloud technology — signals long-term innovation focus. A co-innovation center in London is designed to compress the journey from drug target to first human application. The same day brought a Dutch court ruling in Novo's favor, an injunction against Ceban Ziekenhuisfarmacie over compounded semaglutide nasal sprays — a small but symbolically meaningful win in the broader fight against copycat products.

These are solid developments, but none are near-term catalysts for the share price.

The technical picture reinforces the nervousness. The stock's RSI sits at 40.6 — not oversold, but firmly in weak territory. It trades 4.7 percent below its 50-day moving average and 2.2 percent below the 200-day average, leaving it beneath virtually every relevant trendline. Annualized volatility of 40 percent tells its own story about how the market is pricing this equity right now.

The interim dividend of DKK 3.75 per share, scheduled for August 14, offers some ballast for income-focused investors, but it doesn't address the structural question: Can Novo defend its leadership in oral GLP-1s when Lilly arrives with a more convenient product?

For now, the risks appear to outweigh the rewards — not because Novo is mismanaging its business, but because competitive pressure is landing at a moment when investor confidence is already fragile. Until the Capital Markets Day in September, uncertainty is likely to dominate the share price. The split analyst opinions capture that dynamic precisely: nobody wants to commit before the company lays its cards on the table.